Nouscom’s NOUS-209 has secured FDA Fast Track designation for Lynch Syndrome cancer prevention, leveraging a shared neoantigen approach to enable an off-the-shelf manufacturing model.AllSci
In contrast, new research highlights the complexity of immune regulation, identifying neoantigen-specific cytotoxic Tr1 CD4 T cells as potential suppressors of immunotherapy efficacy.nature.com
Nothing published in the last 14 days cleared the bar. Below is the most relevant background we're tracking.
Relevant work from earlier we're still surfacing — not today's news.